90 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform. Over the past
8-K
EX-10.4
406w5jjkj2pvmlye0 3w
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
xuyujyt
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
mow6gbaw96ntg
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
le8d6kyhu8
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
jlm0 jfbt
30 May 23
Business combination disclosure
4:21pm
8-K
83i5q3yxd6wiarotg
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
80l64
22 May 23
Business combination disclosure
7:01am
8-K
dbc8oenkyzcs1j
22 May 23
Other Events
6:59am
8-K
EX-99.1
jnsn c9fhc6
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
0dx5 7jw7q185lav5j
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
56i urdk6d
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm